New anticoagulants demonstrated promising outcomes across multiple trials, including a 34% reduction in bleeding events with asundexian compared to apixaban.
Systematic Review
Do novel anticoagulants improve clinical outcomes and safety compared to standard therapies in patients with thromboembolic disorders?
This systematic review highlights that while novel anticoagulants offer promising efficacy and safety profiles across various indications, patient-specific tailoring and monitoring remain essential.
Background: Thromboembolic disorders globally contribute to morbidity and mortality, emphasizing adequate anticoagulation and thrombosis management. Therapeutic advances are essential in preventing complications like pulmonary embolism, stroke, and myocardial infarction. This review summarizes recent anticoagulation advances, current challenges, future directions, and novel anticoagulants and drug delivery systems on clinical outcomes. Methods: This paper assesses the effectiveness and safety of new anticoagulants through a systematic review of recent clinical trials, meta-analyses, and guideline publications. Key studies, including PACIFIC-AF, RIVER, ENAVLE, ENVISAGE-TAVI AF, and ARCADIA, were analyzed to provide a perspective on therapeutic advancements. Results: The review highlights key findings from vital clinical trials. Asundexian, in the PACIFIC-AF trial, demonstrated a 34% reduction in bleeding events compared to Apixaban. In the RIVER trial, Rivaroxaban reduced significant bleeding events by 20% compared to warfarin in patients with bioprosthetic mitral valves. In the ENAVLE trial, Edoxaban achieved a 3.7% decrease in thromboembolic events compared to warfarin without increasing significant bleeding rates. In the ENVISAGE-TAVI AF trial, edoxaban was noninferior to VKAs in preventing thromboembolic events but showed a slight increase in major bleeding events by 1.5%. Lastly, the ARCADIA trial highlighted that apixaban did not significantly reduce recurrent stroke risk compared to aspirin, with both treatments having an annualized stroke rate of 4.4%. Conclusion: Advances in anticoagulant therapies and drug delivery systems aim to enhance patients' clinical outcomes for thromboembolic disorders. While recent trials show promising data, ongoing patient-specific responses and monitoring challenges require further research. Continuous innovation and investigation are essential to refine anticoagulation practices and tailor treatments.
Qureshi et al. (Mon,) conducted a systematic review in Thromboembolic disorders. New anticoagulants vs. Standard therapies (warfarin, apixaban, aspirin) was evaluated on Effectiveness and safety (thromboembolic and bleeding events). New anticoagulants demonstrated promising outcomes across multiple trials, including a 34% reduction in bleeding events with asundexian compared to apixaban.